Hemolytic uremic syndrome

Hemolytic uremic syndrome
source
Name	Hemolytic uremic syndrome

Hemolytic uremic syndrome is an acute, systemic condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It most commonly follows infection with certain strains of bacteria and is managed by multidisciplinary teams in tertiary care centers, often involving infectious disease, nephrology, and hematology specialists.

Signs and symptoms

Patients typically present with a triad of red blood cell fragmentation, low platelet counts, and renal impairment, producing clinical features such as pallor, jaundice, petechiae, and oliguria. Common systemic manifestations include fever, abdominal pain, vomiting, and diarrhea after exposure to enteric pathogens; neurologic signs such as seizures, altered mental status, focal deficits, and coma can develop and require consultation with neurologists from institutions like Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and Cleveland Clinic. Extra-renal complications may involve cardiac dysfunction, pancreatitis, pulmonary edema, and hypertension leading to referrals to centers such as Mount Sinai Hospital and Toronto General Hospital.

Causes and pathophysiology

The prototypical cause is infection by shiga toxin–producing bacteria, notably strains implicated in outbreaks linked to food sources investigated by agencies like the Centers for Disease Control and Prevention, Food and Drug Administration, World Health Organization, and public health laboratories in Public Health England. Other etiologies include complement regulatory defects associated with mutations identified in patients seen at academic centers such as University College London Hospitals and Karolinska University Hospital, and associations with pregnancy, transplantation, or medications monitored by regulatory authorities like the European Medicines Agency and National Institutes of Health. Pathophysiology centers on endothelial injury in renal microvasculature, activation of platelets, and formation of thrombi driven by toxins, immune complexes, or dysregulated complement pathways originally elucidated in landmark studies from institutions including Harvard Medical School, University of Oxford, and Stanford University School of Medicine.

Diagnosis

Diagnosis is based on clinical and laboratory criteria evaluated in reference laboratories affiliated with hospitals such as Johns Hopkins Hospital and Massachusetts General Hospital, combining hemoglobin with schistocytes on blood film, thrombocytopenia, and elevated serum creatinine. Microbiological testing for causative agents uses culture or PCR panels performed by labs associated with Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and university microbiology departments at University of California, San Francisco and Imperial College London. Complement assays, ADAMTS13 activity, and genetic testing for mutations in complement regulators are ordered through specialized services at centers like Mayo Clinic and Seattle Children's Hospital to distinguish atypical variants from thrombotic thrombocytopenic purpura cases reported by groups at National Institutes of Health and Columbia University Irving Medical Center.

Treatment

Initial management focuses on supportive care delivered in intensive care units at tertiary centers such as Cleveland Clinic and Johns Hopkins Hospital, including fluid balance, blood transfusion, and renal replacement therapy via hemodialysis or peritoneal dialysis with expertise from units like Royal Free Hospital and Guy's and St Thomas' NHS Foundation Trust. Plasma exchange is indicated in selected cases following protocols developed at Mayo Clinic and Mount Sinai Hospital. Targeted therapies include monoclonal antibodies that inhibit complement activation, used after evaluation at specialty centers such as Hospital for Sick Children, Toronto and UCSF Medical Center, while antimicrobial stewardship guided by Infectious Diseases Society of America recommendations addresses bacterial triggers. Management often requires multidisciplinary coordination with pediatric centers like Great Ormond Street Hospital for children and transplant centers like University of Pennsylvania Health System for post-transplant presentations.

Prognosis and complications

Outcomes vary: many pediatric cases recover with supportive care, whereas adult and atypical cases may progress to chronic kidney disease or end-stage renal disease necessitating long-term dialysis or kidney transplantation performed at institutions like Cleveland Clinic and Mayo Clinic. Neurologic sequelae, hypertension, and cardiac complications contribute to morbidity described in cohort studies from Karolinska Institute, University of Toronto, and University of Tokyo. Relapse risk is notable in complement-mediated forms, leading to long-term follow-up in specialist clinics at National Institutes of Health and regional university hospitals.

Epidemiology

Incidence shows geographic and temporal variation with sporadic cases and outbreaks reported by surveillance bodies such as Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and World Health Organization. Pediatric incidence is higher in regions with documented outbreaks linked to contaminated food or water investigated by agencies including Food and Drug Administration and national public health institutes like Health Canada and Public Health England. Historical clusters studied at academic centers like University of Iowa Hospitals and University of Minnesota inform risk factors and seasonality patterns.

Prevention and public health measures

Prevention emphasizes food safety and outbreak control measures implemented by agencies such as Food and Drug Administration, Centers for Disease Control and Prevention, World Health Organization, and national bodies like Public Health England and Health Canada. Strategies include surveillance, rapid microbiologic testing at reference laboratories, public advisories, and hand hygiene campaigns led by hospitals such as Johns Hopkins Hospital and Mayo Clinic. Vaccination research and antimicrobial stewardship programs are pursued at research institutions including Harvard Medical School, Stanford University School of Medicine, and Imperial College London to reduce incidence and limit transmission.

Category:Kidney diseases